ArticleBlood transfusion = Trasfusione del sangue
Seroprevalence study of West Nile virus and Usutu virus in blood, organs, cells and tissue donors in Italy, 2021-2022.
Article in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Prevalence and characterization of West Nile virus infections among people living with HIV in Northern Italy: a sero-repository analysis.Infection · 2026Article
- Seroprevalence of West Nile virus among blood donors in mainland France, 2021 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWest Nile virus (WNV) and Usutu virus (USUV) are endemic in Italy. Some regions experience high annual circulation, while others report only sporadic or low-level activity. MATERIALS AND
methodsA national survey was conducted to assess WNV and USUV seroprevalence among blood and organ donors. Between February 2021 and February 2022, serum samples were collected from 9,073 donors (8,829 blood donors and 244 organ donors) across almost all Italian regions. Samples were screened using a WNV ELISA IgG test, with positive results confirmed via plaque reduction neutralization test (PRNT) for WNV and USUV.
resultsOf the total samples, 195 (190 blood donors and 5 organ donors) tested positive by ELISA. Among these, 23 samples (20 blood donors and 3 organ donors) were confirmed WNV-positive, and 42 (41 blood donors and 1 organ donor) were USUV-positive by PRNT. Additionally, 39 donors had antibodies to both viruses.Unadjusted national seroprevalence among blood donors was 0.66% (95% CI: 0.50-0.85%) for WNV and 0.90% (95% CI: 0.71-1.11%) for USUV. Among organ donors, WNV seroprevalence was 1.64% (95% CI: 0.45-4.14%) and 0.82% (95% CI: 0.10-2.93%) for USUV. After adjustment by general population weights, national seroprevalence in blood donors was 0.90% for WNV and 1.16% for USUV. DISCUSSION: Seroprevalence was higher in historically endemic northern regions, aligning with known circulation patterns. Blood and organ donors showed similar exposure levels. These findings confirm sustained WNV and USUV presence in Italy and support the continued need for preventive safety measures in the management of Substances of Human Origin (SoHO).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.